Αρχική World News Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy in...

Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy in Patients with Metastatic or Recurrent Cancer

Among 11,947 patients with metastatic or recurrent cancer that spanned across more than 50 different tumour types, 8% of patients had a tumour with germline alteration considered therapeutically actionable and 3.2% of these patients received germline genotype–directed treatment. The study team led by Dr. Zsofia K. Stadler of the Department of Medicine, Memorial Sloan Kettering Cancer Center in New York, NY, USA and colleagues published their findings in August 2021 issue of the Journal of Clinical Oncology. They wrote that germline sequencing analysis is additive to tumour sequencing analysis in terms of therapy selection. Therefore, the multigene germline genetic analysis should be considered for all patients with metastatic or recurrent cancer to guide treatment selection.

The authors explained in the background that tumour mutational profiling is increasingly performed in patients with advanced cancer to identify clinically actionable somatic alterations to guide the systemic therapy. Historically, germline genetic testing has focused more on early-stage cancers to identify cancer predisposition syndromes in patients who would benefit from risk-reducing surgery, chemoprevention, and enhanced cancer surveillance. 

Wider utilisation of multigene germline panels and whole-exome analysis has recently demonstrated that pathogenic germline alterations are quite common in patients with cancer. Universal germline analysis for all patients with ovarian, pancreatic, advanced prostate, and metastatic breast cancers is now endorsed by the US National Comprehensive Cancer Network and tumour testing for markers of Lynch syndrome is recommended for all colorectal and endometrial cancers.

By using a prospective pan-cancer cohort, the study team designed the study to assess the utility of broad germline panel testing for selection of germline-directed therapy and to determine the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer.

From 2015 to 2019, patients with cancer undergoing tumour genomic profiling in their institution were prospectively consented for germline cancer predisposition gene analysis. In patients harbouring germline likely pathogenic or pathogenic alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype–directed therapy were determined.

In total, 2,037 patients (17%) harboured a germline likely pathogenic or pathogenic variant. By oncology knowledge base classification, 1,042 patients (9%) had likely pathogenic or pathogenic variant in a gene with therapeutic implications: 4% level 1, 4% level 3B, and less than 1% level 4. 

BRCA1/2 variants accounted for 42% of therapeutically actionable findings, followed by CHEK2 (13%), ATM (12%), mismatch repair genes (11%), and PALB2 (5%).

When limited analysis to the 9,079 patients with metastatic or recurrent cancer, 710 (8%) harboured level 1 or 3B genetic findings and 289 (3.2%) received germline genotype–directed therapy. Germline genotype–directed therapy was received by 61% and 18% of metastatic cancer patients with level 1 and level 3B findings, respectively, and by 54% of BRCA1/2, 75% of mismatch repair, 43% of PALB2, 35% of RAD51C/D, 24% of BRIP1, and 19% of ATM carriers.

Among those with BRCA1/2 who received PARP inhibitor, 84 of 188 (45%) had tumours other than breast or ovarian cancer, wherein the drug, at time of administration, was delivered in an investigational setting.

The authors commented that with increasing number of genes with germline alterations predictive of drug response and the proliferation of tumour agnostic basket studies assessing germline genotype–directed treatments, the tumour agnostic evaluation of patients with metastatic or recurrent cancer for potentially actionable germline alterations should be considered.

Their study findings indicate that using a multigene panel that incorporates BRCA1/2 and other homologous recombination repair genes, as well as the mismatch repair genes, appears a reasonable for patients with metastatic or recurrent cancers.

The authors also commented that it is needed to tackle in the future standardised classification of the increasing number of germline alterations with therapeutic actionability and the impact of germline-directed therapies in patients with early-stage cancer.

The study was supported in part by the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering; the Precision, Interception and Prevention Program at Memorial Sloan Kettering; the Robert and Kate Niehaus Center for Inherited Cancer Genomics at Memorial Sloan Kettering; the Romeo Milio Lynch Syndrome Foundation; and the US National Institutes of Health National Cancer Institute Cancer Center grant.


Stadler ZK, Maio A, Chakravarty D, et al. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology 2021;39(24):2698-2709. DOI: 10.1200/JCO.20.03661.



Προηγούμενο άρθροCan Cancer Symptoms Be Mistaken for Menopause?
Επόμενο άρθροFoodie Fridays: Watermelon Salad


Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...